Subscribe
shutterstock_1686828337_arrowsmith2
arrowsmith2 / Shutterstock.com
13 October 2022Big PharmaSarah Speight

In conversation with...Beatriz San Martin, Arnold & Porter

The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
Pandemic blues: the global approach to COVID-related IP
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
Pandemic blues: the global approach to COVID-related IP
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
Pandemic blues: the global approach to COVID-related IP
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility